Investors may claim losses after ADMA Biologics shares fell 16.6% amid fraud allegations.

Rosen Law Firm is investigating securities claims against ADMA Biologics following allegations that the company misled investors by inflating revenue through channel stuffing. The stock dropped 16.6% on March 24, 2026, after a short seller report by Culper Research. Investors who purchased ADMA Biologics securities may join a class action lawsuit to seek compensation without upfront fees. The Rosen Law Firm has a strong track record in securities class actions and is preparing to represent affected shareholders.